Andrew Stewart Plump

CEO

Insider activity · 24 months0 buys3 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 2 salesSept 26 · 0 buys · 1 saleOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (3 ops.)

€4.6M

Latest filing published 03 Sept 2026 for TAKEDA PHARMACEUTICAL CO LTD, €1.9M.

Filing timeline

BuySale

Andrew Stewart Plump

Insider track record

Disclosed buys

Disclosed sells

Signal history

Andrew Stewart Plump: trading record in brief

Andrew Stewart Plump appears in our data through filings on Takeda Pharmaceutical Co Ltd shares, published by SEC (Form 4). In total, 5 filings cover trades dated from 27 April 2026 to 2 September 2026.

The open-market record consists of 3 sales worth €4.6M, with no purchase. Other entries cover 2 share grants.

Most recently, on 3 September 2026, the filings show an open-market sale worth €1.9M in Takeda Pharmaceutical Co Ltd. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.